Nath Bio-Genes
NATHBIOGEN NSE
Nath Bio-Genes
FMCGNSE: NATHBIOGEN BSE: 537291 Agricultural Products
Key Fundamentals
MicrocapAgricultural ProductsFMCGMarket Cap
₹280 Cr
Volatility
Moderate
P/E Ratio
7.26
EBITDA
₹52.44 Cr
Return on Equity
5.99%
Debt to Equity
0.2
Book Value
₹358.06
52W High
₹204
52W Low
₹126.15
Tapetide Score
Data-driven rating, 0–100. How it works →
Key Insights
Strengths
2- Stock is trading at 0.41 times its book value
- Debtor days have improved from 110 to 70.0 days.
Weaknesses
5- Tax rate seems low
- Company has a low return on equity of 5.93% over last 3 years.
- Contingent liabilities of Rs.89.3 Cr.
- Earnings include an other income of Rs.15.2 Cr.
- Dividend payout has been low at 9.52% of profits over last 3 years
Growth Rate
Revenue Growth
20.46% lower than
3Y
Net Income Growth
7.85% higher than
3Y
Cash Flow Change
-76.43% lower than
3Y
ROE
-7.85% lower than
3Y
ROCE
-5.73% lower than
3Y
EBITDA Margin (Avg.)
-22.3% higher than
3Y
Quarterly Results
| Particulars | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 235 | 23 | 32 | 43 | 244 | 32 | 37 | 52 | 284 | 44 | 66 | 52 | 328 |
| Expenses | 198 | 18 | 26 | 39 | 207 | 27 | 29 | 52 | 254 | 38 | 62 | 47 | 293 |
| Operating Profit | 37 | 5 | 6 | 4 | 37 | 5 | 8 | 0 | 29 | 6 | 4 | 4 | 35 |
| OPM % | 16% | 22% | 18% | 9% | 15% | 15% | 22% | 0.8% | 10% | 14% | 5% | 9% | 11% |
| Other Income | 0 | 0 | 3 | 1 | 0 | 0 | 0 | 4 | 4 | 4 | 4 | 4 | 3 |
| Interest | 3 | 2 | 3 | 1 | 2 | 3 | 4 | 1 | 3 | 4 | 5 | 5 | 4 |
| Depreciation | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| PBT | 34 | 2 | 5 | 3 | 34 | 1 | 4 | 2 | 29 | 5 | 2 | 2 | 33 |
| Tax % | 1% | 19% | 17% | 19% | 1% | -3% | 30% | 30% | 2% | 12% | 35% | 100% | 2% |
| Net Profit | 33 | 2 | 4 | 3 | 33 | 1 | 3 | 1 | 28 | 5 | 2 | 0 | 32 |
| EPS in Rs | 17.59 | 0.79 | 2.02 | 1.38 | 17.55 | 0.58 | 1.39 | 0.78 | 14.88 | 2.54 | 0.84 | -0.01 | 16.98 |
Profit & Loss
| Particulars | Mar 2012 | Mar 2013 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM |
|---|---|---|---|---|---|---|---|---|
| Sales | 97 | 109 | 230 | 234 | 248 | 268 | 445 | 490 |
| Expenses | 82 | 89 | 193 | 185 | 198 | 217 | 393 | 440 |
| Operating Profit | 15 | 20 | 37 | 49 | 50 | 51 | 52 | 49 |
| OPM % | 15% | 18% | 16% | 21% | 20% | 19% | 12% | 10% |
| Other Income | 1 | 1 | -87 | 1 | 4 | 4 | 14 | 15 |
| Interest | 2 | 4 | 11 | 10 | 9 | 11 | 16 | 17 |
| Depreciation | 5 | 5 | 3 | 3 | 3 | 4 | 4 | 4 |
| PBT | 9 | 12 | -63 | 36 | 42 | 41 | 46 | 43 |
| Tax % | -1% | 4% | 6% | 3% | 5% | 5% | 10% | — |
| Net Profit | 9 | 12 | -67 | 35 | 40 | 39 | 42 | 39 |
| EPS in Rs | 5.75 | 7.34 | -35.46 | 18.43 | 20.85 | 20.31 | 21.91 | 20.35 |
| Div. Payout % | 0% | 0% | -6% | 11% | 10% | 10% | 9% | — |
Balance Sheet
| Particulars | Mar 2012 | Mar 2013 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|
| Equity Capital | 16 | 16 | 19 | 19 | 19 | 19 | 19 |
| Reserves | 30 | 41 | 523 | 554 | 591 | 625 | 661 |
| Borrowings | 11 | 19 | 93 | 105 | 110 | 123 | 138 |
| Other Liabilities | 63 | 82 | 105 | 114 | 160 | 259 | 278 |
| Total Liabilities | 120 | 158 | 739 | 793 | 880 | 1,026 | 1,097 |
| Fixed Assets | 21 | 38 | 245 | 244 | 249 | 250 | 249 |
| CWIP | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Investments | 1 | 0 | 5 | 5 | 6 | 6 | 6 |
| Other Assets | 99 | 121 | 490 | 543 | 625 | 770 | 842 |
| Total Assets | 120 | 158 | 739 | 793 | 880 | 1,026 | 1,097 |
Cash Flow
| Particulars | Mar 2012 | Mar 2013 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|
| Operating | — | — | 17 | 38 | 75 | 18 | -13 |
| Investing | — | — | -20 | -3 | -27 | -4 | 3 |
| Financing | — | — | -22 | -2 | -8 | -2 | -4 |
| Net Cash Flow | — | — | -25 | 34 | 39 | 11 | -13 |
| Free Cash Flow | — | — | 16 | 36 | 48 | 10 | -16 |
| CFO/OP | — | — | 54 | 80 | 150 | 37 | -22 |
Ratios
| Particulars | Mar 2012 | Mar 2013 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|
| Debtor Days | 47 | 70 | 136 | 152 | 139 | 121 | 70 |
| Inventory Days | 587 | 667 | — | 4,388 | — | — | — |
| Days Payable | 146 | 239 | — | 586 | — | — | — |
| Cash Conversion Cycle | 487 | 499 | 136 | 3,954 | 139 | 121 | 70 |
| Working Capital Days | 79 | 64 | 427 | 415 | 342 | 321 | 253 |
| ROCE % | — | 24% | — | 7% | 7% | 7% | 7% |
Insights
BetaAI-extracted from concalls & annual reports · figures as reported, with sources
Log in to view Nath Bio-Genes insights
63 extracted metrics + investor summaries across FY12–FY27.
Documents
1
Format of the Initial Disclosure to be made by an entity identified as a Large Corporate : Annexure A
11h - Company confirms it is not a large corporate as of 31 March 2026; outstanding long-term borrowing nil. 11h - Company confirms it is not a large corporate as of 31 March 2026; outstanding long-term borrowing nil.
2
NBIL Concall
10h - Audio recording of 5 May 2026 conference call on audited Q4 and FY26 results uploaded. 10h - Audio recording of 5 May 2026 conference call on audited Q4 and FY26 results uploaded.
3
Announcement under Regulation 30 (LODR)-Earnings Call Transcript
10h - Earning Call Transcript held on 05th May 2026 10h - Earning Call Transcript held on 05th May 2026
4
Board Meeting Outcome for Outcome Of Board Meeting
4 May - FY26 audited results, Rs 2 dividend, independent director reappointed, MD pay raised to Rs 1.44 crore. 4 May - FY26 audited results, Rs 2 dividend, independent director reappointed, MD pay raised to Rs 1.44 crore.
5
Announcement under Regulation 30 (LODR)-Investor Presentation
4 May - Investor Presentation on Financial Results as on 31st March 2026 4 May - Investor Presentation on Financial Results as on 31st March 2026
Frequently Asked Questions about Nath Bio-Genes
What does Nath Bio-Genes (India) Ltd do?
Incorporated in 1993, Nath Bio-Genes Ltd
is in the business of Production, Processing,
and Marketing of Hybrid and GM Seeds[1]
Where is Nath Bio-Genes (India) Ltd (NATHBIOGEN) listed?
Nath Bio-Genes (India) Ltd trades as NATHBIOGEN on the NSE and under code 537291 on the BSE.
Which sector does Nath Bio-Genes (India) Ltd belong to?
Nath Bio-Genes (India) Ltd is classified under the FMCG sector, in the Agricultural Products industry.
What is the market capitalisation of Nath Bio-Genes (India) Ltd?
Nath Bio-Genes (India) Ltd has a market capitalisation of ₹280 Cr, which places it in the Small Cap band.
What is the PE ratio of Nath Bio-Genes (India) Ltd?
Nath Bio-Genes (India) Ltd trades at a PE ratio of 7.26, against a book value of ₹358.06 per share.
What is the 52-week high and low of Nath Bio-Genes (India) Ltd?
Over the last 52 weeks Nath Bio-Genes (India) Ltd has traded between ₹126.15 and ₹204.
Does Nath Bio-Genes (India) Ltd pay dividends?
Nath Bio-Genes (India) Ltd has a dividend yield of 1.33%.
What is the Return on Equity (ROE) of Nath Bio-Genes (India) Ltd?
Nath Bio-Genes (India) Ltd reported a return on equity of 5.99%. Its debt-to-equity ratio is 0.20.
Company Information
Incorporated in 1993, Nath Bio-Genes Ltd is in the business of Production, Processing, and Marketing of Hybrid and GM Seeds[1]
Website nathbiogenes.com
CEO Mr. Satish Kagliwal
Employees 451
Listed 2014-01-28
Face Value ₹ 10
Issued Size 1,90,04,000
For AI agents and developers
Reading this as an AI agent, LLM or automated pipeline? Every page on Tapetide is also published as clean Markdown — no navigation, no scripts, just the data. Fetch https://tapetide.com/stocks/NATHBIOGEN.md for Nath Bio-Genes (India) Ltd: company profile, latest price, key fundamentals, the Tapetide Score, growth rates, quarterly and annual financial statements, shareholding pattern, technical indicators, analyst ratings and exchange filings.
Append .md to any Tapetide URL for the
same treatment. A full index of what we publish is at /llms.txt and /llms-full.txt. For live,
structured queries instead of documents, use our MCP server.